The Danish group has licensed an unnamed product with an unknown mechanism.

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Biogen’s acquisition of Reata lifted the third quarter’s M&A value above $13bn, but data from Evaluate show that acquisition activity cratered in both August and September.

The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.